Through this 100% online program, you will handle the most modern urological diagnostic techniques to create personalized intervention plans that optimize patients' overall well-being significantly” 

According to a new study conducted by the World Health Organization, Urological Diseases affect more than 250 million people globally. In this sense, the institution foresees that this rate will increase significantly in the coming years due to factors such as the aging of the population, changes in lifestyle or the increase in the prevalence of chronic pathologies. In the face of this reality, practitioners need to stay at the forefront of the latest innovations in the field of urology to improve clinical outcomes and reduce the burden of these conditions. 

In this context, TECH has created a pioneering program in Update in Urology. Designed by references in this field, the academic itinerary will delve into issues ranging from the particularities of the molecular biology of cancer or the use of the most modern diagnostic techniques to assess the clinical status of patients to the use of the latest generation of technological tools such as multiparametric magnetic resonance imaging. As a result, graduates will acquire advanced clinical skills to develop personalized treatment plans, lead multidisciplinary teams and apply the latest therapeutic innovations to improve the quality of life of patients.

Regarding the methodology of this program, TECH offers a 100% online educational environment, which allows physicians to combine their studies with the rest of their regular responsibilities. It also employs its unique Relearning system, based on the repetition of key concepts to fix knowledge and facilitate the updating of knowledge. The only requirement is that professionals have a device with Internet access, even their own cell phone. 

In this way, they will be able to enter the Virtual Campus to enjoy an educational experience that will elevate their career horizons to a higher level. In addition, the program will include the participation of renowned International Guest Directors, who will give detailed Masterclasses.

Prestigious International Guest Directors will give exclusive Masterclasses that will help you master sophisticated techniques such as reconstructive procedures” 

This Advanced master’s degree in Update on Urology contains the most complete and up-to-date scientific program on the market. The most important features of the program include:

• Practical cases presented by experts in Urology
• The graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice
• Practical exercises where the self-assessment process can be carried out to improve learning
• Its special emphasis on innovative methodologies in urological clinic practice
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

You will delve into the integration of sophisticated technology such as Focal Therapies, which will help you increase accuracy and adherence to urological treatments” 

Its teaching staff includes professionals from the field of Urology, who contribute their work experience to this program, as well as renowned specialists from leading companies and prestigious universities.

The multimedia content, developed with the latest educational technology, will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide an immersive learning experience designed to prepare for real-life situations.

This program is designed around Problem-Based Learning, whereby the student must try to solve the different professional practice situations that arise throughout the program. For this purpose, the professional will be assisted by an innovative interactive video system created by renowned and experienced experts.

Thanks to the Relearning system used by TECH, you will reduce the long hours of study and memorization. You will update your knowledge in a natural way!"

You will design individualized therapeutic strategies for the optimal approach to diseases such as renal carcinoma"

The teaching materials that integrate this program have been elaborated by true referents in Urology, taking into account the most recent innovations in this area. The curriculum will delve into issues ranging from the molecular biological foundations of cancer or therapeutic advances in the approach to testicular cancer to the use of state-of-the-art technological instruments such as multiparametric magnetic resonance imaging. As a result, graduates will develop advanced clinical skills to apply treatments with precision and manage complex urological clinical cases with greater accuracy. 

You will delve into the use of robotic technologies, advanced laparoscopy and Artificial Intelligence tools to optimize clinical outcomes”

Module 1. Update in Oncological Principles, Functional Sequelae and Supportive Treatment of Patients with Urologic Tumors

1.1. Molecular Biology of Cancer
1.2. Prognostic Factors, Tumor Markers and Paraneoplastic Syndromes in Urologic Oncologic Pathology
1.3. Tumor Genetics
1.4. Oncologic Emergencies in Urology
1.5. Oncologic Principles: Etiology, Susceptibility, Epidemiological
1.6. Principles of Urologic Surgical Oncology
1.7. Clinical Trials in Urologic Oncology Patients
1.8. Supportive Care of the Oncologic Patient in Urology
1.9. Genitourinary Functional Sequelae of Oncologic Treatments in Urology.

1.9.1. Surgical Andrology
1.9.2. Reconstructive Surgery

1.10. Nuclear Medicine and Molecular Imaging in Oncologic Tumor Pathology

1.10.1. Scientific Evidence in Urologic Oncology
1.10.2. New Tracers

Module 2. Advances in the Diagnosis, Treatment and Monitoring of Non-Muscle Invasive Bladder Carcinoma

2.1. Epidemiology and Etiopathogenesis
2.2. Pathologic Anatomy

2.2.1. TNM
2.2.2. WHO
2.2.3. Biopsies/Samples
2.2.4. Risk Factors
2.2.5. Other Factors: T1A-A, Lymphovascular Invasion, Variants, Markers, etc.
2.2.6. CIS

2.3. Diagnosis Part I

2.3.1. Clinical Symptoms
2.3.2. Imaging Tests
2.3.3. Urine Cytology
2.3.4. Molecular Markers (Clinical Applications to Date)

2.4. Diagnosis Part II

2.4.1. Cystoscopy
2.4.2. Photodynamic Diagnosis
2.4.3. NBI
2.4.4. Second TURP

2.5. Risk Groups

2.5.1. EORTC
2.5.2. Risk and Progression Charts; CUETO
2.5.3. CIS

2.6. Adjuvant Treatment with Chemotherapy

2.6.1. Single Dose Post-TURP
2.6.2. Adjuvant
2.6.3. Options to Increase Efficiency

2.7. Adjuvant Treatment with BCG

2.7.1. Advantages
2.7.2. Strains
2.7.3. Toxicity and Treatment
2.7.4. Dose
2.7.5. Treatment Plans

2.8. Endovesical Alternatives

2.8.1. Doxorubicin
2.8.2. Epirubicin
2.8.3. Gemcitabine
2.8.4. Onco Thiotepa

2.9. Adjuvant Treatment of CIS
2.10. Treatment Plans in the Event of Standard Treatment Failure

2.10.1. Definition of Failure
2.10.2. After Chemotherapy
2.10.3. After BCG

2.11. Radical Cystectomy in Non-Muscle Invasive Bladder Carcinoma

2.11.1. Fundamentals
2.11.2. Immediate vs. Early Onset
2.11.3. After BCG Failure

2.12. Monitoring

Module 3. Advances in the Diagnosis, Treatment and Monitoring of Muscle Invasive Bladder Carcinoma

3.1. Pathologic Anatomy

3.1.1. Lymph Node Involvement
3.1.2. Margins
3.1.3. Histological Variants
3.1.4. Muscle Invasion Pattern
3.1.5. Markers: p53, etc
3.1.6. TNM

3.2. Urethral Involvement and Concomitant Prostate Cancer
3.3. Staging

3.3.1. Local: MRI and CT
3.3.2. Lymph Node: MRI; CT; PET
3.3.3. TUS: UROTAC
3.3.4. Future: FDG-PET-CT; DCE-MRI; DWI-MRI

3.4. Radiotherapy

3.4.1. Neoadjuvant
3.4.2. Palliative
3.4.3. Adjuvant

3.5. Neoadjuvant Chemotherapy
3.6. Radical Cystectomy

3.6.1. Risk Assessment
3.6.2. Delay Time
3.6.3. Lymphadenectomy: Extent and Number
3.6.4. Urinary Diversion
3.6.5. Postoperative Complications
3.6.6. Palliative Cystectomy
3.6.7. Laparoscopic vs Robotic Surgery

3.7. Bladder Preservation Programs

3.7.1. TURBT
3.7.2. Radiotherapy
3.7.3. Chemotherapy
3.7.4. Multimodal Treatments

3.8. Neoadjuvant Chemotherapy
3.9. Metastatic Cancer

3.9.1. Poor Prognosis Factors
3.9.2. Prognostic Groups/Adverse Factors
3.9.3. Definition of Cisplatin “Ineligible”
3.9.4. Single-Agent Chemotherapy
3.9.5. Standard Cisplatin "Eligible” Patient Treatment
3.9.6. Alternative/2nd Line Treatment of Cisplatin "Eligible" Patients.
3.9.7. Treating “Ineligible” Patients
3.9.8. Treating Symptomatic Patients

3.10. Monitoring

3.10.1. Treatment of Bone Metastases
3.10.2. Rescue Surgery
3.10.3. Urothelial Recurrence: Urethra and TUS

3.11. Role of Immunotherapy
3.12. Major Ongoing Clinical Trials
3.13. Particularities of Other Histologies

Module 4. Advances in the Diagnosis, Treatment and Monitoring of Testicular Cancer

4.1. Epidemiology and Staging
4.2. Diagnosis and Clinical Staging

4.2.1. Physical Examination
4.2.2. Doppler Ultrasound
4.2.3. Tumor Markers
4.2.4. CAT and MRI
4.2.5. FDG-PET-CAT
4.2.6. TNM

4.3. Staging

4.3.1. Risk Groups
4.3.2. Risk Factors/Prognosis

4.4. Orchiectomy

4.4.1. Indications
4.4.2. Role of Deferred Surgery
4.4.3. Conservative Surgery
4.4.4. Contralateral Biopsy

4.5. Pathologic Anatomy

4.5.1. Role of the Pathologist in the Diagnosis of Testicular Neoplasms
4.5.2. WHO 2016 Classification of Germinal Neoplasms
4.5.3. Diagnostic Algorithm for Non-Germinal Neoplasms
4.5.4. Staging

4.6. Stage I Treatment: Seminoma

4.6.1. Monitoring
4.6.2. Radiotherapy
4.6.3. Adjuvant Chemotherapy
4.6.4. Retroperitoneal Lymphadenectomy
4.6.5. Risk-Adapted Treatment

4.7. Stage I Treatment: Non-Seminoma

4.7.1. Monitoring
4.7.2. Adjuvant Chemotherapy
4.7.3. Retroperitoneal Lymphadenectomy
4.7.4. Risk-Adapted Treatment

4.8. Treatment of Metastatic Germ Cell Tumors
4.9. Residual Tumor Mass
4.10. Systemic Treatment of Tumor Relapse
4.11. Monitoring
4.12. Testicular Stromal Tumors: Diagnosis, Treatment and Monitoring

Module 5. Advances in the Diagnosis, Treatment, and Monitoring of Penile Cancer

5.1. Epidemiology, Etiology, and Risk Factors
5.2. Pathological Anatomy

5.2.1. Premalignant Lesions
5.2.2. Histological Subtypes of Carcinoma of the Penis
5.2.3. TNM
5.2.4. Prognostic Factors
5.2.5. Molecular Biology

5.3. Diagnosis and Staging

5.3.1. Clinical Symptoms
5.3.2. Physical Examination
5.3.3. Imaging Tests: Ultrasound; MRI; CT; PET-CT-FDG

5.4. Images of Penile and Urethral Cancer
5.5. Anatomical Considerations of the Penis and Lymphatic Drainage
5.6. Treatment of Penile Cancer I: Surgical Treatment of the Primary Tumor

5.6.1. Non-Invasive Superficial Disease: CIS
5.6.2. Invasive Disease Confined to the Glans Penis: Ta/T1a
5.6.3. Invasive Disease: T1b/T2

5.6.3.1. Confined to Corpus Spongiosum
5.6.3.2. Invasion of Corpus Cavernosum

5.6.4. Invasive Urethral Disease: T3.
5.6.5. Invasive Disease of Adjacent Structures: T4.

5.7. Treatment of Carcinoma of the Penis II: Lymph Nodes

5.7.1. Daseler's Inguinal Anatomical Zones
5.7.2. General Considerations
5.7.3. Risk Stratification for Nodal Involvement in cN0

5.7.3.1. Monitoring
5.7.3.2. Lymph Node Staging

5.7.4. Modified Lymphadenectomy
5.7.5. Dynamic Sentinel Lymph Node Biopsy

5.7.5.1. cN1/cN2
5.7.5.2. Radical Inguinal Lymphadenectomy
5.7.5.3. Pelvic Lymphadenectomy

5.7.6. cN3
5.7.7. Controversies in Ilioinguinal Lymphadenectomy

5.8. Penile Cancer Treatment III: Radiotherapy

5.8.1. Indications

5.8.1.1. Ta/T1a
5.8.1.2. T2.

5.8.2. Lymph Node Involvement

5.9. Penile Cancer Treatment IV: Systemic

5.9.1. Adjuvant Chemotherapy
5.9.2. Neoadjuvant Chemotherapy
5.9.3. Palliative Chemotherapy
5.9.4. Targeted Therapy

5.10. Monitoring

5.10.1. Overview
5.10.2. Clinical Guides
5.10.3. Local Recurrence
5.10.4. Regional Recurrence

5.11. Quality of Life
5.12. Primary Urethral Carcinoma

Module 6. Advances in the Diagnosis, Treatment and Monitoring of Renal, Suprarenal and Retroperitoneal Carcinoma

6.1. Epidemiology and Etiopathogenesis
6.2. Diagnostic Imaging and Clinical Staging

6.2.1. Doppler and Contrast Ultrasound: Evaluation of Complicated Renal Cyst, Renal Mass and Dissemination
6.2.2. MRI and CT: Diagnosis, Staging and Monitoring

6.3. Pathologic Anatomy

6.3.1. WHO
6.3.2. ISUP
6.3.3. Fuhrman
6.3.4. Clear Cells
6.3.5. Papillary
6.3.6. Chromophobic
6.3.7. Other Histologies

6.4. Renal Tumor Biopsy

6.4.1. Technical Aspects
6.4.2. Indications
6.4.3. Side Effects
6.4.4. Efficacy
6.4.5. Cystic Lesions

6.5. Prognostic Factors

6.5.1. TNM
6.5.2. Histological Factors
6.5.3. Clinical Factors
6.5.4. Molecular Factors

6.6. Localized Renal Carcinoma

6.6.1. Monitoring
6.6.2. Radical Surgery vs. Nephron-Sparing Surgery
6.6.3. Nephron-Sparing Surgery
6.6.4. Adrenalectomy
6.6.5. Lymphadenectomy
6.6.6. Prenephrectomy Embolization
6.6.7. Ablative Treatments

6.7. Advanced Localized Renal Carcinoma

6.7.1. cN+
6.7.2. Unresectable Tumors
6.7.3. IVC Thrombosis
6.7.4. Adjuvant and Neoadjuvant Treatment
6.7.5. Clinical Trials

6.8. Advanced or Metastatic Renal Carcinoma

6.8.1. The Role of Radical Nephrectomy
6.8.2. Cytoreductive Surgery + Immunotherapy
6.8.3. Role of Metastasectomy
6.8.4. Radiotherapy
6.8.5. Embolization
6.8.6. Symptomatic Treatment of Patients with Renal Carcinoma

6.9. Systemic Treatment

6.9.1. Chemotherapy
6.9.2. Immunotherapy

6.9.2.1. Advances in Immunotherapy
6.9.2.2. α- IFN
6.9.2.3. IL-2.
6.9.2.4. Vaccines and Targeted Immunotherapies

6.9.2.4.1. Tumor Antigen 5T4 + 1st Line Therapies
6.9.2.4.2. Anti PD-1 or PD-L1 Antibodies

6.9.3. Targeted Therapy

6.9.3.1. Advances in Targeted Therapy
6.9.3.2. IMDC Risk/Prognostic Groups: Therapeutic Implication
6.9.3.3. Tyrosine Kinase Inhibitors
6.9.3.4. Monoclonal Antibodies Against Circulating VEGF
6.9.3.5. mTOR Inhibitors

6.9.4. 1st Line Treatment: Sunitinib
6.9.5. 2nd Line Treatment: Pazopanib
6.9.6. 1st Line Treatment: Other Options
6.9.7. 1st Line Treatment in Patients with Poor Prognosis: Temsirolimus
6.9.8. 1st Line Treatment Positioning
6.9.9. 2nd Line Treatment: Axitinib
6.9.10. 2nd Line Treatment: Everolimus
6.9.11. 2nd Line Treatment: Cabozantinib
6.9.12. 2nd Line Treatment: Nivolumab
6.9.13. 2nd Line Treatment: Subsequent Options
6.9.14. Therapeutic Sequencing in Renal Carcinoma: Treatment Positioning
6.9.15. Symptomatic Treatment of Patients With Renal Carcinoma
6.9.16. Non-Clear Cell Carcinomas

6.10. Monitoring

6.10.1. Imaging Tests
6.10.2. Recurrence: Local and Distant
6.10.3. Ablative Treatments

6.11. Drug Resistance Mechanism
6.12. Major Developments in Metastatic Kidney Cancer: Ongoing Clinical Trials
6.13. Suprarenal Mass

6.13.1. Differential Diagnosis
6.13.2. Functioning Mass Diagnosis
6.13.3. Surgical Treatment
6.13.4. Metastatic Cancer

6.14. Primary Retroperitoneal Tumors

6.14.1. Differential Diagnosis
6.14.2. Diagnostic Techniques
6.14.3. Surgical Treatment
6.14.4. Metastatic Cancer

Module 7. Advances in the Diagnosis, Treatment and Monitoring of Prostate Cancer

7.1. Epidemiology and Risk Factors
7.2. Diagnosis

7.2.1. TR
7.2.2. PSA: Density, Kinetics, Ratio, PHI, etc.
7.2.3. Other Markers: Genetic, PCA3, 4K, etc.
7.2.4. Prostate Biopsy

7.3. Screening vs. Early Diagnosis
7.4. Diagnostic Imaging

7.4.1. Ultrasonography: Sonoelastography, Contrast, Histoscanning, etc.
7.4.2. Bone Scan
7.4.3. CAT
7.4.4. MRI
7.4.5. PET-CAT
7.4.6. mpMRI: Technical Aspects

7.5. Pathologic Anatomy

7.5.1. Biopsies
7.5.2. RP Piece

7.6. Clinical and Pathologic Staging
7.7. Deferred Treatment

7.7.1. Localized Prostate Cancer: AS vs. WW
7.7.2. Locally Advanced
7.7.3. Metastatic

7.8. Localized Prostate Cancer

7.8.1. RT: General Information

7.8.1.1. IMRT/IGRT
7.8.1.2. Dose Escalation
7.8.1.3. Hormone Therapy
7.8.1.4. RxT + CT
7.8.1.5. Dose Escalation + Hormone Therapy

7.8.2. PR: General Information

7.8.2.1. Surgical Technique: Open-Laparoscopic-Robotic
7.8.2.2. Conservation of Neurovascular Bundles

7.8.3. Focal Therapy

7.9. Radical Prostatectomy

7.9.1. Low-Risk
7.9.2. Medium-Risk
7.9.3. High-Risk and Locally Advanced
7.9.4. Lymphadenectomy and Lymph Node Involvement
7.9.5. Adjuvant and Neoadjuvant Hormone Therapy
7.9.6. Conservation of Neurovascular Bundles: Indications and Results

7.10. Radiotherapy

7.10.1. Low-Risk
7.10.2. Medium-Risk
7.10.3. High-Risk
7.10.4. Locally Advanced: MRC P23/PR07; TAP 32; SPCG-7/SFUO-3
7.10.5. Ganglion Chains: RTOG 85-31; UK-STAMPEDE
7.10.6. Proton Therapy
7.10.7. Low-Dose-Rate Brachytherapy
7.10.8. High-Dose-Rate Brachytherapy
7.10.9. RxT after RP: EORTC 22911; ARO; SWOG 8794
7.10.10. Nodes

7.11. Cryosurgery
7.12. HIFU7.13. Focal Therapy

7.13.1. Negative Biopsy + Elevated PSA
7.13.2. mpMRI
7.13.3. Biomarkers
7.13.4. Future
7.13.5. PI-RADS Scientific Evidence
7.13.6. Ultrasound-Guided Prostate Biopsy +MRNR

7.13.6.1. Advances in Ultrasound-Guided Prostate Biopsy
7.13.6.2. Material
7.13.6.3. Technique: Transrectal/Transperineal

7.13.7. Fusion Biopsy
7.13.8. Cognitive Biopsy
7.13.9. Scientific Evidence
7.13.10. Cost-Effectiveness of MRI in the Detection of Prostate Cancer
7.13.11. Focal Therapy: Index Lesion; Clonal Theory
7.13.12. Selection Criteria. Risk Stratification
7.13.13. Energy Sources: HIFU, Cryotherapy, Brachytherapy, Electroporation, Photodynamic Therapy, Cyberknife
7.13.14. Monitoring and Recurrence

7.14. Metastatic Prostate Cancer

7.14.1. Standard Treatment: Hormone Therapy
7.14.2. SWOG: Risk Groups
7.14.3. Intermittent Blocking

7.15. Castration Resistance: Etiology
7.16. CRPC Definition New Criteria
7.17. Clinicopathological Prognostic Factors in CRPC. Androgen Deprivation in mCPRC. Response Markers
7.18. Non-Metastatic CRPC (CRPC-M0). Clinical Management. Monitoring Criteria
7.19. Hormonal Maneuvers in CRPC. Scientific Evidence
7.20. 1st Line Chemotherapy Treatment: Docetaxel

7.20.1. mCRPC
7.20.2. CRPC

7.21. Non-1st Line Chemotherapy Treatment: Cabazitaxel. Other Drugs
7.22. Hormone Treatment in CRPC: Abiraterone

7.22.1. mCRPC
7.22.2. CRPC

7.23. Hormone Treatment in CRPC: Enzalutamide

7.23.1. mCRPC
7.23.2. CRPC

7.24. Treatment with Bone-Targeted Agents

7.24.1. Bisphosphonates
7.24.2. Denosumab
7.24.3. Radium-223

7.25. Immunotherapy in mCRPC
7.26. Symptomatic Treatment of Patients with CRPC
7.27. Treatment Algorithm in CRPC: Positioning and Sequencing
7.28. Mechanisms of Resistance to Hormonal Treatment in CRPC: AR-V7 and Other Related Factors
7.29. Molecular Biology of CRPC: BRCA and Related Genes
7.30. Molecular Biology of CRPC: Epigenetic. Angiogenesis
7.31. Molecular Biology of CRPC: Other Molecular Pathways Involved
7.32. Main Ongoing Clinical Trials in CRPC
7.33. Future Outlook of CRPC

Module 8. Latest Advances in Surgical Anatomy Laparoscopic Anatomy

8.1. Upper Surgical Anatomy
8.2. Lower Surgical Anatomy
8.3. Surgical Anatomy of the Pelvic Floor

Module 9. Basic Aspects of Urologic Surgery

9.1. Basic Periopertaive Aspects
9.2. Instrumentation and Drainage of the Urinary Tract
9.3. Basic Principles of Endourology.
9.4. Basic Principles in a Laparoscopy, Minilaparoscopy and 3D
9.5. Basic Principles in Robot Assisted Laparoscopic Surgery
9.6. Basic Principles in Single Port Laparoscopic Surgery
9.7. Basic Principles in Surgery Notes/e-Notes

Module 10. Latest Advances in Diagnosis and Treatment Techniques in Urology

10.1. Flexible Cystoscopy
10.2. Prostate Ultrasound
10.3. Testicular Ultrasound / Testicular Doppler
10.4. Penile Ultrasound / Penile Doppler
10.5. Intravesical Instillation of Drugs
10.6. Pyelography
10.7. Adult Urodynamic Study
10.8. Pediatric Urodynamic Study
10.9. Prostate Biopsy
10.10. Multiparametric MRI
10.11. Bone Scanning
10.12. PET-CAT
10.13. Isotopic Renogram

Module 11. Latest Trends in Suprarenal and Retroperitoneal Surgical Pathology

11.1. Right Adrenalectomy
11.2. Left Adrenalectomy
11.3. Partial Adrenalectomy
11.4. Surgery for Adrenal Carcinoma
11.5. Excision of Retroperitoneal Tumors

Module 12. Latest Trends in Renal Surgical Pathology

12.1. Open Radical Nephrectomy with Cava Thrombus
12.2. Laparoscopic Intra/Retro Peritoneal Nephrectomy
12.3. Partial Nephrectomy / Off Clamp Lumpectomy
12.4. Partial Nephrectomy / Selective Lumpectomy or Supraselective Clamping
12.5. Living Donor Nephrectomy
12.6. Focal Treatment of Renal Tumors

Module 13. New Advances in the Field of Kidney Transplant

13.1. Renal Extraction
13.2. Heterotopic Renal Transplant
13.3. Orthotopic Renal Transplant
13.4. Robotic Renal Transplant
13.5. Renal Autotransplantation
13.6. Ureteroneocystostomy. Types

Module 14. New Advances in the Field of Vascular Kidney Transplant

14.1. Renal Artery Stenosis: Percutaneous Treatment
14.2. Renal Artery Stenosis: Surgical Treatment
14.3. Renal Artery Aneurysm. Percutaneous Treatment
14.4. Renal Artery Aneurysm. Surgical Treatment
14.5. Renal Embolization post NLP and NP

Module 15. Latest Trends in Surgical Pathology of the Upper Urinary Tract

15.1. Laparoscopic Nephroureterectomy and Surgical Treatment of the Distal Ureter
15.2. Endoscopic Treatment of the Upper Urinary Tract Tumors
15.3. Percutaneous Nephrostomy
15.4. Lithiasis Fragmentation Methods: Energy Types
15.5. Percutaneous Nephrolithotomy in Prone Position
15.6. Percutaneous Nephrolithotomy in Supine Position
15.7. "Mini Percutaneous" Nephrolithotomy: Types
15.8. Retrograde Intrarenal Surgery (CRIR or RIRS)
15.9. Combined Antegrade and Retrograde Surgery (ECIRS / microECIRS)
15.10. Ureteral Access Sheaths. Types and Compatabilities
15.11. Extracorporeal Shock Wave Lithotripsy (ESWL)
15.12. Semi-Rigid Ureteroscopy (SRU): Microureteroscopy (Micro-URS)
15.13. Antiretroviral Mechanisms and Techniques
15.14. Endourologic Treatment of Infundibular Stenosis Diverticulum
15.15. Pyeloplasty and Special Laparoscopic Considerations in Children
15.16. Treatment of Ureteral Stenosis: Prosthesis
15.17. Treatment of Ureteral Stenosis: Sections
15.18. Ureteral Replacement and Reimplantation
15.19. Uretero-Intestinal Stenosis: Endoscopic Treatment
15.20. Uretero-Intestinal Stenosis: Surgical Treatment

Module 16. Latest Trends in Bladder Surgical Pathology

16.1. Randomized Bladder Biopsy. Bladder TUR. Bloc TUR. Laser
16.2. Hexvix / SPIES / NBI-Assisted Bladder TUR
16.3. Laparoscopic Partial and Radical Cystectomy in Males with Urethrectomy: Open Bypass
16.4. Laparoscopic / Robotic Cystectomy in Females: Laparoscopic Bypass
16.5. Lymphadenectomy in Bladder Cancer
16.6. Open and Endoscopic Cystostomy / Cystolithotomy
16.7. Vesicoureteral Reflux Surgery
16.8. Bladder Diverticulum Surgery

Module 17. Latest Trends in Prostate Surgical Pathology

17.1. Prostate TUR: Trigonocervicoprostatotomy
17.2. Prostatic Vaporization
17.3. Prostatic Enucleation
17.4. Prostatic Adenomectomy
17.5. Urolift. I-Tind
17.6. Prostate Prosthesis
17.7. Laparoscopic / Robotic Radical Prostatectomy
17.8. Radical Prostatectomy with Hydrodissection
17.9. Prostatic Radiotherapy (IMRT) / Prostatic Brachytherapy
17.10. Focal Therapy: Cryotherapy
17.11. Focal Therapy: HIFU (High Intensity Focused Ultrasound)
17.12. Focal Therapy: Electroporation
17.13. Lymphadenectomy in Prostate Cancer

Module 18. Latest Trends in Urethra Surgical Pathology

18.1. Endoscopic Treatments of Urethral Lithiasis
18.2. Posterior Urethroplasty
18.3. Anterior Urethroplasty
18.4. Hypospadias Surgery in Children
18.5. Hypospadias Surgery in Adults
18.6. Urethral Fistulas
18.7. Female Urethra Stenosis
18.8. Urethral Diverticulum Surgery in Women
18.9. Regenerative Medicine in Urethral Pathology

Module 19. Latest Trends in Penile Surgical Pathology

19.1. Gland Decortication and Penectomy
19.2. Penile Incurvation Surgery
19.3. Penis Prothesis
19.4. Lymphadenectomy in Penile Cancer

Module 20. Latest Trends in Scrotal and Testicular Surgical Pathology

20.1. Vasectomy and Vasovasostomy
20.2. Surgical Treatment of Varicocele
20.3. Surgical Treatment of Hydrocele
20.4. Orchidopexy
20.5. Orchiectomy
20.6. Sperm Retrieval Techniques
20.7. Lymphadenectomy in Testicular Cancer

Module 21. New Advances in the Surgical Treatment of Urinary/ Pelvic Floor Incontinence

21.1. Stress Urinary Incontinence
21.2. Emergency Urinary Incontinence
21.3. Treatment of Recurrent Stress Urinary Incontinence
21.4. Treatment of Vesico-Vaginal Fistula
21.5. Pelvic Prolapse Surgery
21.6. Urinary Incontinence in Men

Make the most of this opportunity to surround yourself with expert professionals and learn from their work methodology"